N-Boc-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid

We are N-Boc-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid CAS:851784-82-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N-Boc-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid
CAS.NO:851784-82-2
Synonyms:N-Boc-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid
2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid
 
Physical and Chemical Properties:
Density 1.379±0.06 g/cm3
Boiling Point 468.5±45.0 °C at 760 mmHg
Molecular Formula C15H17Cl2NO4
Molecular Weight 346.206
Flash Point 237.1±28.7 °C
Vapour Pressure 0.0±1.2 mmHg at 25°C
Index of Refraction 1.580
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Lifitgrast.

N-Boc-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid


Related News: ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.Bromuro de 3-fluorobencilo CAS:456-41-7 ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.11-bromo-13,13-dimetil-13H-indeno [1,2-b] antraceno CAS:1214723-03-1 ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.2-hydroxy-6-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%.Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.

Related Products
Product Name
1,4-Naphthalenedione View Details
UV Absorber HMS View Details
4-Fluorobenzeneboronic acid View Details
4-Methylbenzotrifluoride manufacturer 2-Thiophenethiol manufacturer 3-Nitrophthalonitrile manufacturer chloromethyl butanoate Cas:33657-49-7 manufacturer Chain Extender 3700 manufacturer